ReviewCell and tissue research2018
The neurobiology of impulse control disorders in Parkinson's disease: from neurotransmitters to neural networks.
Review in Cell and tissue research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 44 citations in OpenAlex.
- Serotonergic cortico-limbic and executive network dysfunction in Parkinson's disease impulse control disorders: a PET-fMRI study.NPJ Parkinson's disease · 2026Article
- Prediction of impulse control disorders in Parkinson's disease through a longitudinal machine learning study.NPJ Parkinson's disease · 2026Article
- Neuropsychological aspects of impulse control disorders in Parkinson's disease.Frontiers in aging neuroscience · 2026Review
- Investigating the Interplay Between the Nrf2/Keap1/HO-1/SIRT-1 Pathway and the p75NTR/PI3K/Akt/MAPK Cascade in Neurological Disorders: Mechanistic Insights and Therapeutic Innovations.Molecular neurobiology · 2025Review
- Trait Impulsivity as a Feature of Parkinson's Disease Treatment and Progression.Parkinson's disease · 2024Review
- A circuit-based approach to modulate hypersexuality in Parkinson's disease.Psychiatry and clinical neurosciences · 2023Article
- White matter microstructures in Parkinson's disease with and without impulse control behaviors.Annals of clinical and translational neurology · 2022Article
- Impulse Control Disorders in Parkinson's Disease: Has COVID-19 Related Lockdown Been a Trigger?Movement disorders clinical practice · 2021Article
- Abnormal Topological Network in Parkinson's Disease With Impulse Control Disorders: A Resting-State Functional Magnetic Resonance Imaging Study.Frontiers in neuroscience · 2021Article
- The Impact of Compulsivity and Impulsivity in Cerebellar Ataxia: A Case Series.Tremor and other hyperkinetic movements (New York, N.Y.) · 2020Article
- Pavlovian bias in Parkinson's disease: an objective marker of impulsivity that modulates with deep brain stimulation.Scientific reports · 2020Article
- The effect on deep brain stimulation of subthalamic nucleus and dopaminergic treatment in Parkinson disease.Medicine · 2020Article
- Using rodent models to understand interactions between gambling and substance use.Current opinion in behavioral sciences · 2020Article
- Compulsive eating behaviors in Parkinson's disease.Eating and weight disorders : EWD · 2019Article
- Roles of PI3K/AKT/GSK3 Pathway Involved in Psychiatric Illnesses.Diseases (Basel, Switzerland) · 2019Review
- Medications, Deep Brain Stimulation, and Other Factors Influencing Impulse Control Disorders in Parkinson's Disease.Frontiers in neurology · 2019Review
- Impulse Control Disorders in Parkinson's Disease. A Brief and Comprehensive Review.Frontiers in neurology · 2019Article
- Disruption of Multiple Distinctive Neural Networks Associated With Impulse Control Disorder in Parkinson's Disease.Frontiers in human neuroscience · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Impulse control disorders (ICD) are common neuropsychiatric disorders that can arise in Parkinson's disease (PD) patients after commencing dopamine replacement therapy. Approximately 15% of all patients develop these disorders and many more exhibit subclinical symptoms of impulsivity. ICD is thought to develop due to an interaction between the use of dopaminergic medication and an as yet unknown neurobiological vulnerability that either pre-existed before PD onset (possibly genetic) or is associated with neural alterations due to the PD pathology. This review discusses genes, neurotransmitters and neural networks that have been implicated in the pathophysiology of ICD in PD. Although dopamine and the related reward system have been the main focus of research, recently, studies have started to look beyond those systems to find new clues to the neurobiological underpinnings of ICD and come up with possible new targets for treatment. Studies on the whole-brain connectome to investigate the global alterations due to ICD development are currently lacking. In addition, there is a dire need for longitudinal studies that are able to disentangle the contributions of individual (genetic) traits and secondary effects of the PD pathology and chronic dopamine replacement therapy to the development of ICD in PD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.